Mark Levis is an Oncology physician affiliated with Johns Hopkins University. OpenAlex indexes 599 publications with 26,380 citations (h-index 83); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
600 N Wolfe St
Baltimore, MD 212870005
Telephone
410-955-8964Registry record last updated 11 Feb 2013.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma IncProgram year20255 payments$15,734openpaymentsdata.cms.gov ↗
- Astellas Pharma US IncProgram year202511 payments$15,177openpaymentsdata.cms.gov ↗
- Daiichi Sankyo Inc.Program year202510 payments$12,853openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
39.2%Other protein kinase inhibitors16.2%Xospata100%Part D≥12 patientsIsocitrate Dehydrogenase 1 Inhibitor8.4%Tibsovo100%Part D<11 patients+ 3 more classes in this area
Anti-infectives
24.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor19%Valacyclovir100%Part D≥31 patientsShort-acting sulfonamides3.5%Sulfamethoxazole-Trimethoprim100%Part D<11 patients+ 1 more class in this area
Cardiovascular
11.4%Loop diuretic2.6%Furosemide100%Part D<11 patientsBeta blocker2.5%Metoprolol Succinate100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2003–2012 per NIH RePORTER. The latest:
- Incorporating FLT3 inhibitors into AML treatment regimens
Johns Hopkins University
FY2012$330,091R01CA128864 - Incorporating FLT3 inhibitors into AML treatment regimens
Johns Hopkins University
FY2011$330,091R01CA128864 - Incorporating FLT3 inhibitors into AML treatment regimens
Johns Hopkins University
FY2010$340,300R01CA128864
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>
Journal of Clinical Oncology
2024 - Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Journal of Clinical Oncology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Roger Blumenthal, MD
Johns Hopkins University
Erin Michos, MD
Johns Hopkins University
Morgan Grams, MD
Johns Hopkins University
Mario Eisenberger, MD
Johns Hopkins University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”